Article thumbnail
Location of Repository

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity

By Antonina Accardo-Palumbo, Anna Rita Giardina, Francesco Ciccia, Angelo Ferrante, Alfonso Principato, Rosalia Impastato, Ennio Giardina and Giovanni Triolo
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2911900
Provided by: PubMed Central

Suggested articles

Citations

  1. (1992). Ayed K: Abnormalities of T lymphocyte subsets in Behçet' s disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies.
  2. (2005). G: NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum
  3. (2002). Humoral and cell mediated immune response to cow's milk proteins in Behçet's disease. Ann Rheum Dis
  4. (2006). Salvarani C: New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol
  5. (2009). Triolo G: One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int
  6. (2010). Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and humour necrosis factor receptor II and interleukin-12 receptor B1 expression in active disease.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.